Related Experiment Video
Updated: Jan 21, 2026

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
Published on: April 23, 2021
The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer
Inna M Yasinska1, Svetlana S Sakhnevych1, Ludmila Pavlova2
1Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom.
Abstract:
Human cancer cells operate a variety of effective molecular and signaling mechanisms which allow them to escape host immune surveillance and thus progress the disease. We have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9 are involved in the immune escape of human acute myeloid leukemia (AML) cells. These cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway. We hypothesized that the Tim-3-galectin-9 pathway may be involved in the immune escape of cancer cells of different origins. We found that studied breast tumors expressed significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues of the same patients and that these proteins were co-localized. Increased levels of LPHN2 and expressions of LPHN3 as well as FLRT3 were also detected in breast tumor cells. Activation of this pathway facilitated the translocation of galectin-9 onto the tumor cell surface, however no secretion of galectin-9 by tumor cells was observed. Surface-based galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3 and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range of human cancer cells and is possibly involved in prevention of anti-tumor immunity.
Insights
Human cancer cells, including breast cancer, utilize the Tim-3 and galectin-9 pathway for immune evasion. This pathway, involving latrophilin 1 and FLRT3, protects cancer cells from immune attack.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Human cancer cells employ molecular mechanisms to evade immune surveillance, facilitating disease progression.
- The Tim-3 (T-cell immunoglobulin and mucin-domain containing-3) and galectin-9 pathway was previously implicated in immune escape for acute myeloid leukemia (AML) cells.
- Cancer cells utilize neuronal receptors like latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich transmembrane protein 3 (FLRT3) to activate signaling pathways.
Purpose of the Study:
- To investigate the involvement of the Tim-3-galectin-9 pathway in the immune escape of various human cancer types.
- To determine if breast tumors exhibit altered expression of Tim-3, galectin-9, LPHN isoforms, and FLRT3.
- To assess the functional role of surface-expressed galectin-9 in protecting cancer cells from cytotoxic T cells.
Main Methods:
- Comparative analysis of Tim-3 and galectin-9 expression in breast tumor tissues versus healthy breast tissues.
- Detection of LPHN isoforms (LPHN1, LPHN2, LPHN3) and FLRT3 expression in breast tumor cells.
- Assessment of galectin-9 translocation to the cell surface and its effect on breast carcinoma cell survival against cytotoxic T cells.
- Screening of diverse cancer cell lines (brain, colorectal, kidney, liver, prostate, lung, skin, blood/mast cell) for Tim-3 and galectin-9 expression.
Main Results:
- Breast tumors showed significantly higher co-localized expression of galectin-9 and Tim-3 compared to healthy tissues.
- Increased expression of LPHN2, LPHN3, and FLRT3 was observed in breast tumor cells.
- Activation of the pathway led to galectin-9 translocation to the tumor cell surface, enhancing protection against cytotoxic T cell-mediated death.
- Tim-3 and galectin-9 were detected in a wide range of cancer cell lines, with most expressing LPHN isoforms and FLRT3.
Conclusions:
- The Tim-3-galectin-9 pathway is utilized by a broad spectrum of human cancer cells for immune evasion.
- This pathway, potentially involving LPHN and FLRT3, plays a role in preventing anti-tumor immunity across various cancer types.
- Targeting the Tim-3-galectin-9 pathway may offer a therapeutic strategy to enhance anti-cancer immune responses.
More Related Videos
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanisms of Retrovirus-induced Cancers
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Global Regulatory Systems

